BACKGROUND
Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes that recognize riboflavin-derived metabolites presented by the monomorphic major histocompatibility complex (MHC)-class I-related molecule MR1. MAIT cells are highly enriched in the human liver and are increasingly implicated in liver...
Yan-Ruide Li, Xin-Yuan Shen, Yi-Chen Zhu et al.· i Medicina· 0 citations
This study indicates the safety and preliminary therapeutic potential of intratumoral injection and suggests it may be a promising strategy for mitigating systemic toxicity; however, further research is necessary to validate its therapeutic efficacy.
Yong Ou, Jian Zhang, H. Tan et al.· Frontiers in Immunology· 0 citations
CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...
Yan-Ruide Li, Yi-Chen Zhu, Yu-Ning Chen et al.· The Oncologist· 0 citations
HSPC-derived AlloESO-T cells are established as an off-the-shelf, mono-specific cytotoxic T cell therapy with scalable manufacturing, enhanced efficacy, and improved safety, which support broad applicability of AlloESO-T cells across solid tumors.
Yi-Chen Zhu, Jia-Ji Yu, Y. J. Kim et al.· Cell Reports Medicine· 0 citations
The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.
